We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+9.12%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.4B
AUM Growth
-$236M
(-9%)
Cap. Flow
-$395M
Cap. Flow
% of AUM
-16.46%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
97
New
20
Increased
44
Reduced
26
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$85.4M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$45.1M |
| 3 |
Merck
MRK
|
+$36.1M |
| 4 |
Edwards Lifesciences
EW
|
+$21.1M |
| 5 |
CMRX
Chimerix, Inc.
CMRX
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$80.2M |
| 2 |
AGN
Allergan plc
AGN
|
+$63.6M |
| 3 |
Viatris
VTRS
|
+$58.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$54.9M |
| 5 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$48.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PTC Therapeutics
PTCT
$6.37B
| $29.6M | 1.23% |
614,742
-138,399
| -18% | -$8.07M |
|
|
RLYP
27
DELISTED
RELYPSA INC COM
RLYP
| $27.9M | 1.16% |
842,030
+4,200
| +0.5% | +$144K |
|
|
SHPG
28
DELISTED
Shire pic
SHPG
| $27.5M | 1.15% |
113,812
-135,047
| -54% | -$33.5M |
|
29
Abbott
ABT
$180B
| $26.6M | 1.11% |
541,734
+57,358
| +12% | +$2.75M |
|
|
30
Viatris
VTRS
$20.1B
| $25.6M | 1.07% |
376,951
-829,887
| -69% | -$58.6M |
|
|
ZSPH
31
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $24.4M | 1.02% |
465,839
+246,536
| +112% | +$12.1M |
|
|
32
Edwards Lifesciences
EW
$47.6B
| $22.2M | 0.93% |
+934,950
| New | +$21.1M |
|
|
CMRX
33
DELISTED
Chimerix, Inc.
CMRX
| $21.9M | 0.92% |
+474,900
| New | +$19M |
|
|
CLVS
34
DELISTED
Clovis Oncology, Inc.
CLVS
| $21.7M | 0.91% |
246,952
-2,200
| -0.9% | -$188K |
|
|
35
Teva Pharmaceuticals
TEVA
$35.9B
| $21.3M | 0.89% |
359,832
-1,300,751
| -78% | -$80.2M |
|
|
XLRN
36
DELISTED
Acceleron Pharma
XLRN
| $20.6M | 0.86% |
652,084
+52,900
| +9% | +$1.71M |
|
37
Karyopharm Therapeutics
KPTI
$168M
| $19.4M | 0.81% |
47,531
+380
| +0.8% | +$164K |
|
38
uniQure
QURE
$2.68B
| $17.5M | 0.73% |
+649,800
| New | +$18.5M |
|
39
Intuitive Surgical
ISRG
$121B
| $17.5M | 0.73% |
325,692
+53,973
| +20% | +$3.02M |
|
|
NXTM
40
DELISTED
NxStage Medical Inc.
NXTM
| $16.7M | 0.7% |
1,172,196
+296,154
| +34% | +$5.02M |
|
|
IMDZ
41
DELISTED
Immune Design Corp.
IMDZ
| $16.7M | 0.7% |
810,390
+743,263
| +1,107% | +$17.6M |
|
42
Novartis
NVS
$295B
| $16.6M | 0.69% |
188,052
+54,796
| +41% | +$5.03M |
|
43
HCA Healthcare
HCA
$84.8B
| $16M | 0.67% |
175,945
+8,769
| +5% | +$703K |
|
|
NVTA
44
DELISTED
Invitae Corporation
NVTA
| $13.8M | 0.58% |
929,765
+55,374
| +6% | +$788K |
|
45
Dr. Reddy's Laboratories
RDY
$9.82B
| $13.7M | 0.57% |
1,238,570
-3,406,240
| -73% | -$37.6M |
|
46
Cigna
CI
$76.6B
| $13.5M | 0.56% |
83,052
+6,587
| +9% | +$910K |
|
|
HTWR
47
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $13M | 0.54% |
178,574
+24,759
| +16% | +$1.93M |
|
48
TG Therapeutics
TGTX
$8.58B
| $12.8M | 0.53% |
772,017
+335,933
| +77% | +$5.32M |
|
|
NVO
49
Novo Nordisk
NVO
$216B
| $11.9M | 0.5% |
434,950
+45,400
| +12% | +$1.28M |
|
|
SGNT
50
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $11.3M | 0.47% |
465,625
-704,458
| -60% | -$16.9M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, Sectoral Asset Management held 97 positions worth $2.4B, down 9% from $2.63B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sectoral Asset Management withdrew a net $395M in Q2 2015, closing 6 positions and reducing 26 holdings. Its most notable exit was Keryx Biopharmaceuticals Inc, an estimated $48.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Regeneron Pharmaceuticals worth $89.2M.
- Sectoral Asset Management's largest Q2 2015 buy was Regeneron Pharmaceuticals: 174,900 shares worth $89.2M.
- Sectoral Asset Management added most to Alexion Pharmaceuticals in Q2 2015, an estimated $45.1M increase.
- Sectoral Asset Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $80.2M.
- Sectoral Asset Management fully exited Keryx Biopharmaceuticals Inc in Q2 2015, selling an estimated $48.7M.
- Sectoral Asset Management's ten largest holdings make up 49% of its $2.4B portfolio in Q2 2015.
- Sectoral Asset Management opened 20 new positions and closed 6 in Q2 2015.
- Sectoral Asset Management's portfolio value fell 9% quarter-over-quarter to $2.4B.
Based on Sectoral Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.